Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine by Pool, Martin et al.
  
 University of Groningen
Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth
Factor Receptor Family for Precision Medicine
Pool, Martin; de Boer, H. Rudolf; Lub-de Hooge, Marjolijn N.; van Vugt, Marcel A. T. M.; Vries,





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Pool, M., de Boer, H. R., Lub-de Hooge, M. N., van Vugt, M. A. T. M., & Vries, de, E. G. E. (2017).
Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor
Receptor Family for Precision Medicine. Theranostics, 7(7), 2111-2133. https://doi.org/10.7150/thno.17934
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019






2017; 7(7): 2111-2133. doi: 10.7150/thno.17934 
Review 
Harnessing Integrative Omics to Facilitate Molecular 
Imaging of the Human Epidermal Growth Factor 
Receptor Family for Precision Medicine 
Martin Pool1*, H. Rudolf de Boer1*, Marjolijn N. Lub-de Hooge2, 3, Marcel A.T.M. van Vugt1#, Elisabeth 
G.E. de Vries1# 
1. Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 
2. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 
3. Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 
* Co-first author 
# Co-senior author  
 Corresponding authors: Elisabeth G.E. de Vries, MD, PhD, Marcel A.T.M. van Vugt, PhD, Department of Medical Oncology, University of Groningen, 
University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands +31 50 3612934 (EGEdV) / +31 50 3615002 (MATMvV) 
e.ge.de.vries@umcg.nl / m.vugt@umcg.nl 
© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license 
(https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. 
Received: 2016.10.15; Accepted: 2017.03.02; Published: 2017.05.27 
Abstract 
Cancer is a growing problem worldwide. The cause of death in cancer patients is often due to 
treatment-resistant metastatic disease. Many molecularly targeted anticancer drugs have been 
developed against ‘oncogenic driver’ pathways. However, these treatments are usually only 
effective in properly selected patients. Resistance to molecularly targeted drugs through selective 
pressure on acquired mutations or molecular rewiring can hinder their effectiveness. This review 
summarizes how molecular imaging techniques can potentially facilitate the optimal 
implementation of targeted agents. Using the human epidermal growth factor receptor (HER) 
family as a model in (pre)clinical studies, we illustrate how molecular imaging may be employed to 
characterize whole body target expression as well as monitor drug effectiveness and the 
emergence of tumor resistance. We further discuss how an integrative omics discovery platform 
could guide the selection of ‘effect sensors’ - new molecular imaging targets - which are dynamic 
markers that indicate treatment effectiveness or resistance. 
Key words: Molecular imaging, cancer therapy, personalized medicine, EGFR, HER2, HER3, drug resistance. 
Introduction 
Cancer is the third leading cause of death in the 
world and mortality is expected to rise (1, 2). Despite 
current state-of-the-art treatment options, many 
cancer patients will ultimately die due to metastatic 
disease. In the last few decades, new insights in 
biological processes underlying cancer led to a flood 
of rationally designed targeted drug candidates (3). 
However, these targeted agents have not reached 
their full potential due to inadequate patient selection, 
which may partly be solved by enrichment of patient 
populations using specific biomarkers (3). Underlying 
reason for these patient sub-populations is 
inter-tumor heterogeneity caused by genotypic and 
phenotypic differences between tumors of similar 
histopathological subtype (4). Similarly, within and 
between tumor lesions of a single patient (intra-tumor 
heterogeneity), drug target and biomarker 
expressions are neither homogeneous nor static (4). 
Thus, high degrees of intra-tumor heterogeneity in 
acquired mutations and target expression levels can 
lead to clonal heterogeneity, an outgrowth of 









failure (5, 6). Furthermore, pathway rewiring can lead 
to acquired resistance. Combined, these factors 
prevent or circumvent efficacy of targeted drugs (7), 
requiring advanced detection tools to determine 
tumor heterogeneity, biomarker expression dynamics 
for improving patient selection, and monitor 
treatment efficacy. In this review, we will discuss how 
molecular imaging may complement molecular 
testing to facilitate patient selection and monitor drug 
efficacy. We will also review discovery platforms for 
novel imaging markers that signify response or 
resistance to molecularly targeted treatments. 
Molecular imaging is well-suited for 
visualization and clinical assessment of biological 
processes, as it can non-invasively and quantitatively 
monitor whole-body marker expression (8, 9). By 
comparing the uptake of imaging tracers across all 
lesions and between patients, the tumor 
heterogeneity, drug delivery, and biological responses 
to drug treatment can be assessed before clinical 
progression becomes apparent by conventional 
techniques, e.g. biopsies and anatomical imaging (8). 
Furthermore, molecular imaging has the potential to 
monitor ‘effect sensors’, early response biomarkers 
providing insight into the functional changes at the 
cellular level that reflect the effectiveness of treatment 
or emergence of resistance mechanisms. 
We will also explore various techniques and 
platforms that can be utilized for identification, 
selection and molecular imaging of drug targets and 
effect sensors. The role of the human epidermal 
growth factor receptor (HER) family in human 
cancers has been extensively studied. Consequently, 
multiple HER-targeted agents are in clinical use and 
many HER-targeted imaging strategies and resistance 
mechanisms have been reported (10). Therefore, we 
will use the known crosstalk, resistance mechanisms 
and effect sensors of the HER family as a model. 
Search Strategy 
Public data base searches were performed on 
PubMed, ClinicalTrials.gov and Google Scholar for 
combinations of the following search terms: “EGFR”, 
“HER2”, “HER3”, “HER4”, “c-MET”, “VEGF-A”, 
“Src”, “ImmunoPET”, “PET”, “SPECT”, “molecular 
imaging”, “fluorescence imaging”, ‘’near-infrared”, 
“nuclear imaging”, ‘’optoacoustic imaging”, 
“resistance”, “breast cancer”, “lung cancer”, “gastric 
cancer”, “colorectal cancer”, “systems biology”, 
“integrative omics”, “genomics”, “transcriptomics”, 
“proteomics”, “mass spec”, “biomarker”, and 
“treatment response”. 
Important abbreviations 
Protein-related; EGFR: epidermal growth factor 
receptor; HER: human EGFR family; HER2-4: human 
EGFR 2-4; RTK: receptor tyrosine kinase; c-MET: 
cellular-mesenchymal to epithelial transition factor; 
HSP90: heat shock protein-90; Src: Rous sarcoma 
oncogene cellular homolog 
Cancer-related; CRC: colorectal cancer; NSCLC: 
non-small cell lung cancer; HNSCC: head and neck 
squamous cell carcinoma; TKI: tyrosine kinase 
inhibitor; mAb: monoclonal antibody 
Imaging; SPECT: Single photon emission 
computed tomography; PET: positron emission 
tomography; CT: computed tomography; Zr: 
zirconium; In: indium; Ga: Gallium; Cu: Copper; Tc: 
technetium; I: iodine; F: fluorine; C: carbon; NIRF: 
near-infrared fluorescence; 800CW: IRDye 800CW 
Omics; CNAs: copy number aberrations; PTMs: 
post-translational modifications; MS: mass 
spectrometry; TCGA: The Cancer Genome Atlas 
consortium  
HER family pathways and resistance in 
cancer 
HER family signaling  
To understand how HER-targeted imaging 
strategies could potentially benefit patients, it is 
important to identify the HER-mediated signal 
transductions, which are the underlying processes 
determining treatment efficacy. The HER family 
consists of four receptor tyrosine kinases (RTKs); 
epidermal growth factor receptor (EGFR), HER2, 
HER3 and HER4 (also ERBB1-ERBB4). HER members 
function through homo- or heterodimerization to 
stimulate proliferation, cell survival, and metastasis 
(Figure 1A) (11). Like most RTKs, HER proteins 
comprise an extracellular ligand-binding domain and 
an intracellular ATP-dependent tyrosine kinase (TK) 
domain. Ligand-induced conformational changes in 
HER family proteins allow for dimerization, which 
promotes transphosphorylation of tyrosine residues 
in TK domains of dimerization partners leading to 
downstream protein kinase B (AKT) and extracellular 
signal-regulated kinase (ERK) pathway activation 
(12,13). Various ligands non-exclusively bind to 
EGFR, HER3 and HER4, as listed in Figure 1C (11). In 
contrast, no ligand is known to bind HER2. Rather, 
HER2 conformation allows constitutive dimerization 
making it the preferred dimerization partner for other 
HER family members (14). HER3 only has weak 
intrinsic kinase activity and thus mainly depends on 
heterodimerization for phosphorylation of six unique 
tyrosine residues in the C-terminal tail, initiating 
potent downstream signaling (15–17).  






Figure 1. Involvement of HER family in cancer treatment and resistance A) Ligand binding to HER family members induces homo- or hetero-dimerization. 
Transphosphorylation of kinase domains then induces a downstream phosphorylation cascade including PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways. B) 
Cancers that dependent on HER family activity can be treated using mAbs or TKIs. Binding of mAbs can inhibit receptor function by preventing dimerization or ligand 
binding, or by inducing internalization and degradation. Small molecule TKIs inhibit transphosphorylation by blocking the ATP binding pockets, either of the receptors 
or downstream signaling nodes. C) Multiple mechanisms of resistance to HER family-directed therapy have been discovered. Expression of truncated variant 
HER2-p65 or EGFRvIII prevent antibody binding, while gatekeeper mutations in EGFR limit binding of erlotinib or gefitinib to TK domain of EGFR (left panel). Inhibition 
of HER signaling can be restored by interactions with non-HER family members, namely c-MET, IGF1R or Src (middle panel). Lastly, compensatory feedback 
mechanism exist within the HER family, where inhibition of HER2 induces expression and activation of HER3 to restore PI3K/AKT signaling (right panel). 
 
HER family receptors in cancer and treatment 
resistance 
HER ligands are aberrantly expressed in various 
cancers and HER family members, especially EGFR 
and HER2, are oncogenic drivers upon mutation or 
amplification (Figure 1) (10). Therefore, several 
HER-directed therapeutics have been developed 
including small molecule tyrosine kinase inhibitors 
(TKIs) and monoclonal antibodies (mAbs) (Figure 1B) 
(10). The HER2 mAb trastuzumab increases overall 
survival of patients with metastatic disease and of 
patients with HER2-positive breast cancers in the 
adjuvant setting (18). Nevertheless, resistance to 
HER-directed treatments frequently occurs (Figure 
1C). Resistance can develop from selective pressure 
on existing or de novo mutations, which circumvent 
drug action (19). Alternatively, treatment resistance 
can develop through rewiring of parallel signaling 
pathways often involving other RTKs taking over the 
proliferative drive (19–24). Although not all 
mechanisms of treatment resistance are understood, 
multiple mechanisms that drive resistance to 
HER-directed agents have been elucidated 
underscoring the need for preventive and alternative 
treatment strategies. 
Treatment with EGFR-directed mAbs cetuximab 
or panitumumab shows anti-tumor efficacy in a 
subset of colorectal cancer (CRC) patients harboring 
KRAS wild-type (wt) tumors while EGFR TKIs 





gefitinib or erlotinib are not effective due to the 
absence of mutations in EGFR (10). In CRC patients 
with EGFR-wt tumors, resistance to EGFR-directed 
therapeutics can emerge through selection or de novo 
acquisition of oncogenic KRAS mutations (25). In 
contrast to CRC, treatment with EGFR-mAbs in 
non-small cell lung cancer (NSCLC) hardly improves 
clinical outcomes. Yet, treatment with gefitinib and 
erlotinib has an anti-tumor effect in NSCLC patients 
harboring activating mutations in the EGFR TK 
domain (26). Invariably, these patients develop 
resistance, which in ~60% of the patients, is due to the 
EGFR-T790M ‘’gatekeeper’’ mutation that renders 
EGFR insensitive to both gefitinib and erlotinib 
(Figure 1C) (26). To counter this mechanism, second 
and third generation EGFR TKIs with increased 
affinity for EGFR-T790M are in development. The TKI 
afatinib, approved for EGFR-exon 19 deletions or exon 
21 L858R substitutions in NSCLC, is also being 
evaluated in combination with cetuximab in NSCLC 
patients harboring T790M mutations. (27, 28). The 
EGFRvIII mutation, which lacks the ligand-binding 
domain encoded by exons 2–7 leading to constitutive 
kinase activity, is mainly found in glioblastoma 
multiforme. The lack of a ligand-binding domain and 
absence of kinase mutations make that EGFRvIII 
mutant cancers respond poorly to TKIs and EGFR 
mAbs regardless of mAb ability to bind to the 
receptor (29).  
In breast cancer, HER2 is an oncogenic driver 
with 20-25% of breast cancers harboring HER2 
amplification and are classified as HER2-positive. 
Compared to amplifications, HER2 mutations are 
rare. Nevertheless, these mutations are found in ~2% 
of NSCLCs and may render tumors amenable to 
HER2-directed therapy (30). Multiple underlying 
mechanisms have been described for HER2-directed 
trastuzumab treatment resistance. For instance, 
expression of a truncated p95-HER2 isoform hampers 
binding of trastuzumab to HER2 and results in clinical 
trastuzumab resistance (31, 32). Alternatively, 
resistance can develop through increased signaling 
from other RTKs, including EGFR, HER3, insulin-like 
growth factor receptor (IGF1R), and 
cellular-mesenchymal to epithelial transition factor 
(c-MET) (33). Since trastuzumab does not prevent 
interaction between HER2 and other RTKs, the 
HER2-directed mAb pertuzumab was developed to 
prevent dimerization by blocking the 
HER2-dimerization domain (34). In light of this, the 
addition of pertuzumab to trastuzumab and docetaxel 
as first-line treatment resulted in a longer overall 
survival of patients with metastatic breast cancer (35). 
Furthermore, a trastuzumab-based antibody-drug 
conjugate (ADC), ado-trastuzumab emtansine 
(T-DM1), was developed to deliver a potent 
maytansinoid toxin payload to HER2-positive cells. 
Treatment with T-DM1 showed an overall survival 
benefit in patients with HER2-positive breast cancers 
and tumor responses were seen in patients who had 
developed trastuzumab resistance (36). Thus, novel 
treatment and combination strategies, such as the 
addition of pertuzumab or using ADCs, can limit or 
circumvent resistance to trastuzumab.  
Although overlooked for a long time, HER3 
received interest as a drug target when somatic 
mutations were discovered in breast and gastric 
cancers, and when a role for HER3 signaling as a 
resistance mechanism to HER-directed therapeutics 
was revealed (37). Specifically, when HER family 
members are targeted by TKIs, HER3 can re-activate 
downstream signaling, ultimately shifting signaling 
towards increased phosphoinositide-3 kinase (PI3K) 
/AKT activity and increased HER3 expression (20,21). 
Indeed, resistance to the EGFR/HER2-directed TKI 
lapatinib in HER2-positive breast cancer cell lines was 
the result of increased EGFR-HER3 signaling 
complexes induced by autocrine secretion of HER3 
ligand NRG1 (Figure 1C). Notably, NRG1 expression 
was a negative predictor of lapatinib treatment, 
suggesting binding of NRG1 to EGFR-HER3 
complexes as a potential cause of resistance (22). As 
the TK domain of HER3 is virtually inactive, drug 
design for HER3-targeted therapies mainly focuses on 
preventing dimerization using mAbs, which are 
currently being clinically evaluated (37). Additionally, 
changes in HER3 expression or activation might serve 
as an early readout of resistance to EGFR or HER2 
therapy.  
Resistance mechanisms through non-HER 
family receptors and downstream signaling 
nodes 
HER family members also interact with 
non-HER family members (23, 38). The crosstalk 
between RTKs and downstream signaling nodes 
compose of feedback activation loops leading to 
intriguingly complex signaling networks. This 
diversity also underlies many resistance mechanisms 
to drugs that target single components of this 
signaling network and could be potential imaging 
targets to monitor treatment efficacy. 
One dimerization partner that can drive 
resistance to HER-targeting drugs is c-MET, a RTK 
that promotes growth, metastasis, and angiogenesis 
(39). Binding of the ligand hepatocyte growth 
factor/scatter factor (HGF/SF) to c-MET leads to 
homodimerization, autophosphorylation, and 
downstream signaling through PI3K and AKT (40) 
making c-MET a prime suspect for alternative 





signaling after EGFR blockade (23, 40). Indeed, 
resistance to cetuximab or gefitinib in head and neck 
squamous cell carcinoma (HNSCC) and NSCLC cell 
lines involved MET amplification and subsequent 
heterodimerization of HER3 with c-MET (Figure 1C) 
(23,24). Furthermore, in preclinical studies, 
HGF-induced c-MET signaling resulted in resistance 
to gefitinib in NSCLC and lapatinib in breast cancer 
cell lines (19, 41). These reports signify that dual 
targeting of c-MET and EGFR might be necessary to 
prevent the emergence of resistance. Preliminary in 
vitro results have indeed shown synergistic effects of 
combined inactivation of EGFR and c-MET in HNSCC 
and NSCLC cell lines (23, 42, 43). Several c-MET 
targeting agents ranging from TKIs, antibodies 
against c-MET, as well as antibodies against the 
c-MET ligand HGF are currently in phase III clinical 
trials (44).  
Another player in HER family signal 
transduction is Rous sarcoma oncogene cellular 
homolog (Src), a non-receptor TK that regulates cell 
growth, migration, and survival signaling pathways. 
Src interacts with EGFR and HER2 as well as with 
c-MET, IGF1R, platelet-derived growth factor 
receptor (PDGFR) and fibroblast growth factor 
receptor (FGFR) (45). Binding of Src to HER2 
conferred resistance to trastuzumab in human tumor 
cell line models harboring a HER2-exon 16 deletion 
(Figure 1C) (46). In another study, Src activation 
conferred resistance to erlotinib in vitro and in vivo by 
inducing c-MET expression in HNSCC models, which 
could be rescued by genetic or pharmacological 
inactivation of c-MET (47) indicating that Src, at least 
in the selected in vitro models, is a key regulator of 
c-MET-mediated resistance to HER-targeted agents. 
Compensatory signaling upon EGFR inhibition 
can also be mediated by IGF1R. Considerable overlap 
has been observed in the functions of IGF1R and the 
HER family and upregulation of the IGF1R signaling 
axis has been observed to compensate for the loss of 
HER signaling (48). In a retrospective study of 155 
patients with HER2-positive breast cancers treated 
with trastuzumab as an adjuvant, increased 
expression of EGFR and IGF1R and dysregulation of 
the AKT pathway were observed following the failure 
of neoadjuvant or conventional therapy and were 
associated with worse treatment outcome (49). In line 
with these results, IGF1R activation and dimerization 
with HER2 was observed in a trastuzumab-resistant 
clone of the human breast cancer cell line SKBR3 but 
not its parental trastuzumab-sensitive cell line (38). 
Furthermore, resistance to irreversible EGFR TKIs 
was mediated through activation of the 
IGF1R pathway in PC9 NSCLC cells (48). Also, 
epigenetic alterations were shown to drive IGF1R 
engagement in a human cancer cell lines panel, 
causing transient resistance to gefitinib, erlotinib, 
cisplatin and BRAF inhibitor treatment (50). 
Taken together, a theme emerges in which 
inactivation of key HER family members results in 
strong positive feedback on various other RTKs, 
including c-MET, IGF1R, and Src. Ultimately, this 
rewiring restores proliferation and survival signaling 
and results in treatment-resistant clones. How this 
positive feedback is wired at the molecular level is 
unclear, although it seems to converge at reinstating 
AKT or ERK signaling.  
Also, when downstream signaling components 
of the HER pathway are targeted, rapid rewiring and 
activation of parallel pathways were observed. 
Inhibition of PI3K in HER2-positive cell lines resulted 
in activation of FOXO transcription factors and 
upregulation of HER3 (48), which was similar to 
HER2 inhibition (20). Also, PI3K inhibition in 
HER2-overexpressing human breast cancer 
xenografts resulted in acquired dependency on ERK 
signaling (51). Further, inhibition of AKT, the critical 
downstream target of PI3K, induced HER3 expression 
and activation of HER3, IGF1R, and the insulin 
receptor (IR) in human breast cancer, prostate cancer, 
and NSCLC cell lines (52). Likewise, treatment of 
breast cancer cell lines with the mechanistic target of 
rapamycin (mTOR) inhibitor AZD8055 resulted in 
induction of HER proteins and activation of HER3 
specifically (53). The aforementioned resistance 
mechanisms underscore the plasticity of the HER 
family and parallel signaling networks and warrants 
the development of non-invasive diagnostic tools that 
can be applied serially to identify not only which 
tumors respond to anti-HER drugs but also when 
resistance to these agents develops.  
Molecular imaging strategies 
Here, we will discuss how molecular imaging 
strategies might be employed to improve HER 
family-directed treatment with a focus on 
marker-selective imaging agents. Besides imaging 
generic cancer processes such as glucose metabolism 
with 18F-FDG or proliferation by 18F-FLT, 
marker-selective imaging agents can capture a broad 
range of cancer hallmarks (54), which might be 
informative for the efficacy of HER-directed 
treatment. 
Molecular imaging can be performed by various 
modalities, e.g. radionuclide, optical, optoacoustic and 
magnetic resonance imaging, with each modality 
having unique advantages as well as limitations (8). 
Molecular imaging with radionuclides is the most 
widely used technique. The main attractive features of 
radionuclide-based imaging are high signal 





sensitivity and the ability to non-invasively acquire 
quantitative three-dimensional information of whole 
body tracer distribution. For single photon emission 
computed tomography (SPECT) imaging, a 
three-dimensional image is computed from multiple 
two-dimensional images taken at different angles of a 
gamma ray-emitting radioisotope. On the other hand, 
when multiple detectors are used, positron emission 
tomography (PET) imaging can be inherently three 
dimensional, based on the origin of the two 
near-perpendicular 511 keV gamma rays emitted after 
positron annihilation. In contrast to SPECT, physical 
collimators are not necessary for PET resulting in 
higher sensitivity, spatial resolution, and 
corresponding shorter acquisition time for scans 
allowing more temporal resolution to study dynamic 
features (55).  
Accurate quantification of cellular receptor 
levels using molecular imaging agents can be affected 
by - but not limited to - a variety of factors such as 
blood flow, vascular permeability, vascularization, 
lymphatic drainage, cellular internalization rate, 
non-specific binding, blood and interstitial pressure, 
metabolites, number of binding-sites, the enhanced 
permeability and retention effect, as well as tracer 
pharmacokinetics (56, 57). Additional complications 
in quantification, can come from external sources such 
as respiration movements of the subject as well as 
differences between scanners, settings, and 
reconstruction algorithms. The partial volume effect, 
image blurring due to the finite resolution of the 
scanner, and target heterogeneity within the tissues 
contained in the smallest resolution unit (i.e. pixels, 
voxels) can also affect the accuracy of quantification 
(57). To resolve these issues, efforts have been 
directed towards more accurate quantification of 
molecular imaging data, a subject that has been 
expertly reviewed by others (56, 57). 
Radioisotopes for SPECT and PET imaging can 
be incorporated in targeting molecules in various 
ways, e.g. through covalent binding or chelation. 
Selection of the most appropriate radioisotope is 
based on the physical half-life of the radionuclide, 
which should match the biological half-life of the 
imaging agent to balance optimal time for tracer 
accumulation in lesions with sufficient signal 
strength, while minimizing radiation burden. For 
instance, carbon-11 (11C, t1/2 = 20 min, PET) and 
fluorine-18 (18F, t1/2 = 110 min, PET) are often used to 
label small molecules, with little or no alteration of 
their kinetic parameters. In contrast, high molecular 
weight biomolecules, such as antibodies, need 
relatively long-lived radiometals for optimal contrast, 
such as zirconium-89 (89Zr, t1/2 = 78.4 h, PET), 
indium-111 (111In, t1/2 = 67.3h, SPECT) or radiohalogen 
iodine-124 (124I, t1/2 = 100.3 h, PET). Fluorine-18, as 
well as radiometals copper-64 (64Cu. t1/2 = 12.7 h, 
PET), technetium-99m (99mTc, t1/2 = 6.0 h, SPECT) and 
galium-68 (68Ga, t1/2 = 68 min, PET) are well-suited for 
imaging biomolecules with short biological half-lives. 
Besides radionuclide-based imaging, optical 
methods such as near-infrared fluorescence (NIRF) 
and optoacoustic imaging have received increasing 
attention. These techniques combine high resolution 
with real-time signal acquisition in the field of view. 
Advantages of optical methods compared to 
radionuclide-based imaging are the lack of radiation 
burden to patients, ‘’off the shelf’’ availability of tracer 
molecules, and relatively low costs. Limitations of 
optical imaging include the difficulty of signal 
quantitation, limited penetration depth, and a 
restricted field of view. Optical methods, therefore, 
appear most suited for localized organ-level imaging, 
such as intra-operative or endoscopic imaging.  
Molecular imaging capabilities are rapidly 
expanding and many known processes and pathways 
that comprise the hallmarks of cancer can be 
visualized using PET or SPECT tracers (54). In this 
context, molecular imaging can be used to 
non-invasively determine lesion biomarker status to 
facilitate proper patient selection. Labeled drugs or 
analogs thereof can be used to assess drug 
accumulation across lesions. Many HER family 
targeting tracers have been described in the literature. 
The tracers mentioned in this review highlight the 
most important findings within each imaging 
strategy, and are listed in Table 2. For a systematic 
overview of HER-targeted tracers, we refer to 
excellent reviews by others (58,59). 
Target expression imaging 
Molecular imaging may be used in the clinical 
setting to measure HER family expression status in 
multiple tumor lesions simultaneously and to 
visualize the inter-tumor heterogeneity. Measuring 
multiple lesions at once might be relevant as single 
biopsies or small tumor fractions are not an adequate 
representation of all lesions (60). Whether molecular 
imaging can be used to better predict response to 
EGFR-targeted agents is unresolved. However, 
several animal studies showed a correlation between 
EGFR expression of human cancer xenografts and 
uptake of 64Cu-cetuximab, 111In-cetuximab and 
111In-f(ab’)2-cetuximab (61–63). Other preclinical 
studies, however, found discordance between 
xenograft EGFR expression and 89Zr-cetuximab or 
64Cu-cetuximab accumulation. In these studies, EGFR 
overexpression did not necessarily result in 
corresponding high tumor tracer accumulation, 
suggesting that factors other than EGFR expression, 





such as perfusion and vascular permeability might 
influence cetuximab-based tracer tumor uptake (64, 
65). For instance, in a preclinical study circulating 
shed EGFR ectodomain (sEGFR) influenced the 
kinetics and tumor targeting of the EGFR antibody 
tracer 89Zr-imgatuzumab (66). In a patient study, six 
out of 10 metastatic CRC patients showed 
89Zr-cetuximab tumor uptake when administered 
with a therapeutic dose of cetuximab. Four of these six 
patients had clinical benefit of cetuximab therapy, 
while a progressive disease was observed in three out 
of four patients without 89Zr-cetuximab uptake (67). 
Although promising, larger cohorts should be 
screened to establish the value of 89Zr-cetuximab for 
prediction of cetuximab efficacy in metastatic CRC 
colorectal cancer patients (NCT02117466).  
The EGFR TKIs erlotinib and gefitinib display 
higher affinity for oncogenic EGFR mutants. This 
feature can be exploited to selectively image mutant 
EGFR variants and provides an attractive tool for 
assessing heterogeneity in EGFR mutation status. In 
several preclinical studies, there was a higher 
accumulation of 11C-erlotinib in NSCLC and glioma 
xenografts containing activating EGFR mutations in 
exon 19 and 21 when compared to xenografts of 
erlotinib-resistant EGFR-T790M, EGFR-wt, or EGFR 
with activating mutations in its extracellular domain 
(68–70). The 11C-erlotinib volume of distribution was 
higher in patients with NSCLC lesions with EGFR 
activating exon 19 deletion than in lesions from 
patients without activating mutations (Figure 2D, E) 
(71). In another series of 13 NSCLC patients, three out 
of four patients with 11C-erlotinib PET positive lesions 
responded to erlotinib treatment while the best 
response seen in in two out of nine patients with 
11C-erlotinib PET negative lesions was a stable disease 
(72). A case report showed high 11C-erlotinib uptake 
in brain metastases of a NSCLC patient with an exon 
19 mutation in the primary tumor with response to 
erlotinib in both primary tumor and brain metastases, 
underscoring the potential value of mutant-specific 
imaging of EGFR status (73). Imaging with the 
pan-HER TKI afatinib can also be used to visualize 
receptor mutation status. Analysis of 18F-afatinib 
showed higher accumulation in A549 EGFR-wt and 
HCC827 EGFR-exon 19 deletion compared to H1975 
EGFR-T790M human NSCLC cell line xenografts. This 
reflects the affinity of afatinib to EGFR with activating 
mutations (74). 
Analogously, several preclinical imaging studies 
have been performed to visualize EGFRvIII status. 
Specifically, IRDye 800CW (800CW)-panitumumab 
and an 800CW-EGFR affibody bound to EGFR-wt and 
EGFRvIII with similar affinity in a rat glioma model. 
In contrast, 800CW-labeled EGFR ligand EGF 
identified EGFR-wt but not EGFRvIII-expressing 
lesions, reflecting the compromised EGFRvIII 
ligand-binding pocket (75). In another study, the 
124I-IMP-R4−labeled EGFRvIII-specific antibody ch806 
was tested in human glioblastoma 
EGFRvIII-transfected U87MG xenografts expressing 
EGFRvIII; no preferential imaging of EGFRvIII could 
be established since only EGFRvIII cell lines were used 
(76). Another EGFRvIII-specific antibody, 
99mTc-labeled 3C10, displayed over ten-fold higher 
accumulation in EGFRvIII-transfected U87MG human 
glioblastoma xenografts compared with the parental 
U87MG (77). Furthermore, the IRDye 680RD-labeled 
EGFRvIII antibody biotin-4G1 accumulated more in 
EGFRvIII-expressing F98npEGFRvIII than in EGFR-wt 
F98npEGFR rat glioblastoma xenografts (78). Overall, 
evidence exists that EGFRvIII might be distinguished 
from EGFR-wt using EGFRvIII tracers. However, 
more rigorous preclinical and clinical data and 
relevance are required to move this field forward.  
Research on fluorescently labeled proteins 
recognizing EGFR mainly focused on their use as an 
add-on ‘red flag’ technique for intraoperative and 
endoscopic procedures. Both 800CW-cetuximab and 
800CW-panitumumab were tested for detection of 
breast cancer xenograft lesions (79). Also, EGFR 
nanobody 800CW-7D12 could detect 
EGFR-overexpressing A431 human squamous cell 
carcinoma xenografts (80). In a preclinical 
intraoperative study, 800CW-7D12 could visualize 
orthotopic primary tongue tumor xenografts and 
resulting cervical lymph node metastases which were 
otherwise not detectable with the naked eye (81). 
Also, 800CW-cetuximab was successfully used to 
detect EGFR-positive lesions in a preclinical simulated 
colonoscopy of a resected human colon with human 
EGFR-expressing colon cancer HCT116luc xenografts 
stitched into the colon wall (82). 800CW-cetuximab 
was likewise tested in HNSCC patients during 
surgery using wide-field NIR imaging. In these 
patients, tumor-to-background ratios of 4.3 and 5.2 
were observed at 3 to 4 days after infusion of 25 and 
62.5 mg/m2 doses of 800CW-cetuximab respectively 
(83). There was a correlation between the fluorescent 
signal of 800CW-cetuximab and EGFR density in 
excised HNSCC tumors as determined by IHC (84). 
To establish the clinical value of EGFR-targeted 
tracers, multiple clinical studies with 
800CW-cetuximab and 800CW-panitumumab for 
intraoperative procedures and 89Zr-cetuximab, 
11C-erlotinib, and 89Zr-panitumumab for EGFR PET 
imaging are currently pursued (Table 1).  






Figure 2. Molecular imaging strategies of HER family proteins A-C) Expression of cell membrane bound HER2 can be imaged by specific binding of 89Zr-trastuzumab to HER2, leading 
to residualizing of 89Zr in tumor cells due to internalization and subsequent degradation of the antibody-receptor complex. HSP90 inhibition by NVP-AUY922 leads to destabilization and 
degradation of HER family proteins at the plasma membrane, leading to lower antigen availability and reduced tracer uptake. B) PET images of mice scanned with 89Zr-trastuzumab before (Top) 
and after (Bottom) treatment with NVP-AUY922, quantified for 144 hours (122). C) 89Zr-trastuzumab PET imaging of a metastatic breast cancer patient before (Top) and after 3 weeks of 
NVP-AUY922 treatment (Middle), with CT-scan prior to treatment shown in Bottom panel. Quantification of all lesions shows a heterogeneous response with a total average decrease in 
89Zr-trastuzumab uptake after 3 weeks of NYP-AUY922 treatment (125). D,E) Higher accumulation of 11C-erlotinib occurs in tumors with specific activating mutations in EGFR due to its 
higher affinity to the mutated TK compared to EGFR-wt. NSCLC tumors with exon-19 deletion (series A) showed higher uptake compared to EGFR-wt tumors (series B). A1-B1: CT 
fused-parametric 11C-erlotinib Vt; A2-B: CT; A3-B3: 18F-FDG (71) F,G) Imaging of HER3 levels using 64Cu-DOTA-F(ab’)2 can be utilized as effect sensor of AKT inhibitors, as GDC-0068 
specifically induces expression of HER3, but not EGFR, as feedback mechanism of AKT inhibition in mouse xenografts after 72h of treatment (119). H,I) Imaging of intracellular processes can 
be facilitated by TAT-modified antibodies. 111In-DTPA-anti-yH2AX-Tat antibodies visualized the formation of DNA damage foci marked by γ-H2AX treatment upon treatment with irradiation 
of DNA damaging agent bleomycin in mouse xenografts (129). 





Table 1. Overview of ongoing clinical trials with molecular imaging of HER family members and related targets 
Target expression imaging 
EGFR  ClinicalTrials.gov identifiers 
89Zr-cetuximab NCT01691391, NCT02117466, NCT00691548 
89Zr-panitumumab  NCT02192541, NCT00326495 
800CW-cetuximab NCT01987375, NCT02736578 
800CW-panitumumab NCT02415881 
HER2   
89Zr-trastuzumab NCT01420146, NCT02286843, NCT01832051, NCT02065609, NCT01957332, NCT02023996, NCT01565200  
111In-pertuzumab NCT01805908 
68Ga-ABY-025 NCT02095210, NCT01858116 
HER3   
89Zr-RO5479599 NCT01482377 
89Zr-GSK2849330 NCT02345174 
VEGF-A   
89Zr-bevacizumab NCT01894451 
800CW-bevacizumab NCT02113202, NCT01972373, NCT02129933 NCT01508572, NCT02583568, NCT02743975 
Drug accumulation imaging 
EGFR  
700DX-cetuximab (RM-1929) NCT02422979 
HER2    
89Zr-trastuzumab  NCT01565200 
64Cu-trastuzumab NCT01939275 
64Cu-MM-302 NCT01304797 




Table 2. Overview of preclinical and clinical tracers 
Tracer Modality Scaffold Study type Target Remarks Ref 
Target expression       
64Cu-cetuximab PET mAb Preclinical EGFR Correlation with EGFR expression xenografts 62 
111In-cetuximab  SPECT mAb Preclinical EGFR Correlation with EGFR expression xenografts 63 
111In-f(ab’)2-cetuximab  SPECT f(ab’)2 Preclinical EGFR Correlation with EGFR expression xenografts 61 
89Zr-cetuximab  PET mAb Preclinical EGFR No correlation with EGFR expression xenografts 64 
64Cu-cetuximab  PET mAb Preclinical EGFR No correlation with EGFR expression xenografts 65 
89Zr-cetuximab  PET mAb Clinical EGFR Tumor uptake in metastatic colorectal patients 67 
IRDye 800CW-cetuximab  NIRF mAb Preclinical EGFR Detection of breast cancer xenograft lesions  79 
IRDye 800CW-cetuximab  NIRF mAb Preclinical EGFR Detection of implanted EGFR-positive lesions in colonoscopy of a 
resected human colon  
82 
IRDye 800CW-cetuximab  NIRF mAb Clinical EGFR Intraoperative tumor detection in HNSCC patients  83 
IRDye 800CW-cetuximab  NIRF mAb Clinical EGFR Correlation between ex vivo fluorescent signal and EGFR density per 
IHC in excised HNSCC patient tumors 
84 
89Zr-imgatuzumab  PET mAb Preclinical EGFR Influence of circulating shed EGFR on tracer tumor uptake and 
kinetics 
66 
IRDye 800CW-7D12 NIRF nanobody Preclinical EGFR Detected EGFR overexpressing xenografts  80 
IRDye 800CW-7D12 NIRF nanobody Preclinical EGFR Intraoperative visualization of orthotopic primary tongue tumor 




NIRF mAb Preclinical EGFR Detection of breast cancer xenograft lesions  79 
IRDye 
800CW-panitumumab  
NIRF mAb Preclinical EGFR-wt/ 
EGFRvIII 
Similar affinity to EGFR-wt and EGFRvIII-expressing xenografts 75 
IRDye 800CW-EGFR 
affibody  
NIRF affibody Preclinical EGFR-wt/ 
EGFRvIII 
Similar affinity to EGFR-wt and EGFRvIII-expressing xenografts 75 
IRDye 800CW-EGF NIRF ligand Preclinical EGFR-wt/ 
EGFRvIII 
Accumulated in EGFR-wt, but not EGFRvIII-expressing xenografts 75 
99mTc-3C10 SPECT mAb Preclinical EGFR-wt/ 
EGFRvIII 
Accumulated more in EGFRvIII than in EGFR-wt xenografts 77 
IRDye 680RD-biotin-4G1  NIRF mAb Preclinical EGFR-wt/ 
EGFRvIII 
Accumulated more in EGFRvIII than in EGFR-wt xenografts 78 
124I-IMP-R4-ch806 PET mAb Preclinical EGFRvIII Accumulated in EGFRvIII-transfected U87MG xenografts 68 
11C-erlotinib PET TKI Preclinical EGFR-wt/ 
mutEGFR 
Accumulation more in exon 19 and 21 mutated than in EGFR-T790M 
and EGFR-wt xenografts 
68-70 
11C-erlotinib PET TKI Clinical mutEGFR Volume of distribution higher in NSCLC patients with EGFR exon 19 
deletion than in lesions of patients without activating mutations  
71 
11C-erlotinib PET TKI Clinical mutEGFR 3 out of 4 patients with 11C-erlotinib PET positive lesions responded to 
erlotinib, while best response in 11C-erlotinib PET negative lesions 
was stable disease in 2 out of 9 patients  
72 





Tracer Modality Scaffold Study type Target Remarks Ref 
11C-erlotinib PET TKI Clinical mutEGFR Case report of high 11C-erlotinib uptake in brain metastases of EGFR 
exon 19 mutated NSCLC patient which responded to erlotinib 
73 
18F-afatinib  PET TKI Preclinical EGFR/HER
2 
Higher accumulation in EGFR-wt and EGFR-exon 19 deletion, 
compared to EGFR-T790M xenografts 
74 
89Zr-trastuzumab PET mAb Preclinical HER2 Specific uptake in HER2-positive xenografts  86, 88 
89Zr-trastuzumab PET mAb Clinical HER2 Detection of lesions in HER2-positive breast cancer patients 94 
111In-trastuzumab SPECT mAb Clinical HER2 Detection of lesions in HER2-positive breast cancer patients 93 
89Zr-pertuzumab PET mAb Preclinical HER2 Specific uptake in HER2-positive xenografts  79 
111In-ABY-002 SPECT affibody Clinical HER2 Detection of lesions in HER2-positive breast cancer patients 90 
68Ga-ABY-002 PET affibody Clinical HER2 Detection of lesions in HER2-positive breast cancer patients 90 
68Ga-2Rs15d PET nanobody Clinical HER2 Detection of lesions in HER2-positive breast cancer patients 91 




HER3 and HER2-mediated uptake in xenografts  100 
89Zr-lumretuzumab  PET mAb Preclinical HER3 HER3-specific uptake in xenografts 95 
89Zr-lumretuzumab  PET mAb Clinical HER3 Tumor uptake in patients with solid tumors, as well as tumor uptake 
before and after administrating therapeutic doses cold lumretuzumab 
102 
64Cu-DOTA-HER3 F(ab’)2 PET f(ab’)2 Preclinical HER3 HER3-specific uptake in xenografts 96 
68Ga-HEHEHE-Z08698  PET affibody Preclinical HER3 HER3-specific uptake in xenografts 97 
 111In-HEHEHE-Z08698  SPECT affibody Preclinical HER3 HER3-specific uptake in xenografts 98 
99mTc-HEHEHE-Z08699  SPECT affibody Preclinical HER3 HER3-specific uptake in xenografts 99 
 111In-HEHEHE-Z08699  SPECT affibody Preclinical HER3 HER3-specific uptake in xenografts 97 
64Cu-patritumab PET mAb Clinical HER3 Tumor uptake in patients with solid tumors 101 
Accumulation 
IRDye 700DX-cetuximab  NIRF mAb Preclinical EGFR Photoimmunotherapy and detection of lesions 103 
89Zr-cetuximab PET mAb Preclinical EGFR Prediction of accumulation for 88Y- and 177Lu-labeled cetuximab  104 
64Cu-MM-302 PET liposome  Preclinical HER2 Predict deposition, kinetics and efficacy of the parental 
doxorubicin-loaded liposome in xenografted mice and primates 
105, 
106 
89Zr-trastuzumab  PET mAb  Clinical HER2 89Zr-trastuzumab scans to determine intra/interpatient HER2 
heterogeneity and (non-)responders to T-DM1 therapy 
107 
89Zr-trastuzumab  PET mAb  Preclinical HER2 Increased uptake of 89Zr-trastuzumab after N-acetylcysteine treatment 
of MUC4-expressing xenografts 
111 
89Zr-pertuzumab  PET mAb  Preclinical HER2 Enhanced residualization of 89Zr-pertuzumab with concurrent 





PET mAb  Preclinical HER2/ 
VEGF/ 
generic 
Anti-angiogenic agent bevacizumab decreased general antibody 





SPECT mAb  Preclinical HER2/ 
generic 
Anti-angiogenic agent B20-4.1 decreased general antibody tracer 
uptake in xenografts 
112 
89Zr-MMOT0530A PET mAb  Preclinical mesothelin Tumor accumulation of naked antibody version of ADC DMOT4039A  108 
89Zr-MMOT0530A PET mAb  Clinical mesothelin 89Zr-MMOT0530A uptake as predictor for clinical response to the 





PET f(ab’)2 Preclinical EGFR EGFR upregulation after PI3K inhibitor GDC-0941 and AKT inhibitor 
GDC-0068 treatment 
119 
89Zr-MEHD7945A PET mAb Preclinical EGFR/ 
HER3  
EGFR and HER3 upregulation after AKT inhibition by GDC-0068  126 
89Zr-trastuzumab  PET mAb Preclinical HER2 Downregulation of HER2 expression through afatinib treatment 120 
89Zr-trastuzumab  PET mAb Preclinical HER2 HER2 downregulation after HSP90 inhibition with NVP-AUY-922 122 
89Zr-trastuzumab  PET mAb Preclinical HER2 HER2 downregulation after HSP90 inhibition with PU-H71 124 
89Zr-trastuzumab  PET mAb Clinical HER2 HER2 downregulation after HSP90 inhibition with NVP-AUY922 in 
HER2-positive breast cancer patients 
125 
89Zr-trastuzumab F(ab’)2  PET f(ab’)2 Preclinical HER2 Upregulation and stabilization of HER2 at the plasma membrane after 
lapatinib treatment 
121 
89Zr-trastuzumab F(ab’)2  PET f(ab’)2 Preclinical HER2 HER2 downregulation after HSP90 inhibition with 17AAG 121 
AlexaFluor 680-ZHer2:342 NIRF affibody Preclinical HER2 HER2 downregulation after HSP90 inhibition with 17-DMAG 123 
64Cu-DOTA-HER3 F(ab’)2  PET f(ab’)2 Preclinical HER3 HER3 upregulation after AKT inhibition by GDC-0068  119 
89Zr-mAb391  PET mAb Preclinical IG1R IGF1R downregulation after HSP90 inhibition with NVP-AUY-922 115 




89Zr-bevacizumab  PET mAb Preclinical VEGF Downregulation of VEGF-A through everolimus treatment 116 
89Zr-bevacizumab  PET mAb Clinical VEGF Downregulation of VEGF-A through everolimus treatment 117 
89Zr-ranibizumab  PET f(ab’)2 Preclinical VEGF Sunitinib treatment-induced changes in VEGF-A tumor levels 118 
Intracellular processes  
111In-anti-p27kip1-TAT  SPECT mAb  Preclinical p27kip1 Upregulation of p27kip1 after trastuzumab treatment  128 
111In-anti-γH2AX-TAT SPECT mAb  Preclinical phospho- 
H2AX 
Detection of DNA breaks induced by chemo and radiotherapy  129 
111In-anti-γH2AX-TAT SPECT mAb  Preclinical phospho- 
H2AX 
Detection of DNA breaks induced during tumorigenesis of breast 
cancer in BALB/C Neu-T mice 
131 
89Zr-anti-γH2AX-TAT PET mAb  Preclinical phospho- 
H2AX 
Detection of DNA breaks induced by chemo and radiotherapy 130 






HER2 overexpression in breast cancer is 
associated with worse prognosis, if not treated with 
HER2-directed therapy (85). HER2 has therefore been 
extensively studied as an imaging target to select 
patients for HER2-directed therapy (Figure 2A). 
89Zr-trastuzumab as well as 89Zr-pertuzumab showed 
specific uptake in HER2-positive xenografts in mice 
(86–88) while 111In- and 89Zr-trastuzumab, 111In- and 
68Ga-labeled HER2 affibodies and a 
68Ga-HER2-nanobody have been applied in patients 
diagnosed with HER2-positive breast cancer (89–94). 
64Cu- and 89Zr-trastuzumab and 68Ga-ABY-025 PET 
are currently being tested for their value in 
identifying HER2-positive lesions and heterogeneity 
in breast and gastric cancer patients (Table 1).  
As discussed above, HER3 has been implicated 
in many escape mechanisms from HER 
family-targeted therapies. Therefore, early 
identification of changes in HER3 expression might 
serve to identify patients at risk of HER3-mediated 
treatment resistance and possibly for selection of 
patients eligible for HER3-targeted treatment. HER3 
expression levels have been successfully imaged in 
vivo with the antibody 89Zr-lumretuzumab (95) and 
64Cu-DOTA-HER3 F(ab’)2 (96), as well as 99mTc-, 111In- 
and 68Ga-labeled HEHEHE-Z08698 and 
HEHEHE-Z08699 affibodies (97–99) while bispecific 
HER2/HER3 tracer 111In-DTPA-Fab-PEG24-HRG, 
based upon heregulin and a trastuzumab Fab, showed 
HER3 and HER2-mediated uptake in SK-OV-3, 
MDA-MB-468 and BT474 xenografts (100). HER3 
imaging has been studied clinically with 
64Cu-patritumab, revealing tumor uptake in cancer 
patients, as well as high liver uptake which could be 
saturated with pre-administration of 9 mg/kg cold 
patritumab (101). In imaging studies of patients, 
89Zr-lumretuzumab showed a decrease in tracer 
tumor uptake after administration of 400, 800 and 
1600 mg flat doses of unlabeled lumretuzumab when 
compared to a pre-dosing 89Zr-lumretuzumab scan 
with a 100 mg protein dose (102). Another HER3 
antibody tracer, 89Zr-GSK2849330, is currently being 
studied in the clinic (Table 1).  
Imaging of drug accumulation in tumors 
Several imaging probes do internalize after 
binding to their targets. Radiometals 64Cu, 68Ga, 89Zr, 
and 111In have residualizing properties, because these 
highly charged isotopes will remain trapped in cells 
after tracer internalization and subsequent 
catabolization resulting in accumulation of signal over 
time in antigen-expressing tissues. Radiohalogens 
such as 18F and iodine isotopes, and fluorescent dyes, 
on the other hand, are released from the cell after 
catabolization of the imaging probe. Residualizing 
probes will therefore roughly reflect the cumulative 
tracer exposure, while tracers using non-internalizing 
or non-residualizing isotopes approximate antigen 
density and binding capacity of the tracer over time.  
An example of a non-residualizing approach is 
the antibody-photosensitizer conjugate IRDye 700DX 
(700DX)-cetuximab, which was effective in inhibiting 
tumor growth and could simultaneously image 
human triple negative breast cancer xenografts (103). 
700DX-cetuximab is currently being evaluated as dual 
imaging and treatment (theranostic) modality in 
patients with recurrent head and neck cancer (Table 
1). Use of a fluorescent approach to study drug 
accumulation might be feasible for lesions within the 
penetration depth of signal as well as during surgery 
or in endoscopic procedures. Accumulation of 
residualizing radioactive tracers in lesions, on the 
other hand, could be used as a proxy for 
antigen-specific delivery of the toxic payloads of 
ADCs and radio-immunotherapeutic agents. 
89Zr-cetuximab was able to predict the accumulation 
of EGFR-directed radio-immunotherapeutics 88Y- and 
177Lu-labeled cetuximab in A431 xenografts (104). 
Furthermore, a 64Cu-labeled variant of MM-302, a 
HER2-targeting liposome containing doxorubicin, 
was successfully used to predict deposition, kinetics, 
and efficacy of the parental liposome in xenografts 
(105, 106). An ongoing clinical trial assesses whether 
deposition of 64Cu-MM-302 can predict the outcome of 
the doxorubicin-loaded parent liposome therapy in 
advanced breast cancer patients (Table 1). A similar 
approach was already used in 56 breast cancer 
patients receiving 89Zr-trastuzumab PET scans prior 
to T-DM1 therapy to determine intra/interpatient 
HER2 heterogeneity and to identify non-responding 
patients. In this study, 28 out of 39 89Zr-trastuzumab 
PET-positive patients responded to T-DM1 therapy, 
while 14 out of 16 of 89Zr-trastuzumab PET-negative 
patients had a stable or progressive disease (107). 
These results indicated that 89Zr-trastuzumab might 
be used to identify patients who benefit from T-DM1 
therapy. In another study, 89Zr-labeled MMOT0530A, 
the naked antibody component of the 
mesothelin-ADC DMOT4039A, accumulated 
preferentially in human pancreatic cancer xenografts 
(108). 89Zr-MMOT0530A was further tested in 11 
patients with ovarian or pancreatic cancer, revealing a 
large degree of heterogeneity of lesion tracer uptake, 
while PET uptake 4 days post injection correlated 
with IHC staining for mesothelin on a per patient 
basis. However, the small patient sample precluded 
analyses of correlation between lesion 





89Zr-MMOT0530A uptake and clinical response to the 
corresponding ADC DMOT4039A (109).  
Important in this context, residualization of 
tracers can be modulated by therapeutic 
interventions. For instance, multiple antibodies 
targeting the same antigen could lead to enhanced 
residualization, as was shown for 89Zr-pertuzumab 
and concurrent trastuzumab administration in 
HER2-positive xenografted mice (110). Decreased 
steric hindrance of HER2 after administration of 
mucolytic agent N-acetylcysteine increased the 
uptake of 89Zr-trastuzumab in MUC4-expressing 
JIMT1 human breast cancer model (111). Interestingly, 
treatment with anti-angiogenic agents could affect 
uptake and accumulation of tracer through 
modulation of vascularization and permeability for 
macromolecular therapeutics such as antibodies (112, 
113). Specifically, uptake of either 89Zr-labeled 
trastuzumab, bevacizumab, or IgG control antibody 
in xenografts was decreased in animals treated with 
the vascular endothelial growth factor A (VEGF-A) 
antibody bevacizumab due to vascular normalization 
(112,113). We envision that molecular imaging 
strategies could be employed for rationally designing 
drug combinations to increase deposition of drugs in 
tumors and possibly increase efficacy, for instance of 
ADCs. Importantly, such strategies can also instruct 
which treatment combinations should be avoided.  
Imaging treatment effects  
As therapies often elicit changes in expression, 
membrane localization and dynamics of proteins, 
such changes could potentially be used as ‘effect 
sensors’ to monitor treatment response (Figure 2F). 
Assessment of functional treatment effects has been 
performed by measuring cell membrane proteins and 
ligands for which expression is known to be 
modulated upon successful target engagement. As an 
example, the VEGF receptor (VEGFR) ligand VEGF-A 
was potently down-regulated after heat shock 
protein-90 (HSP90) inhibition and consequently led to 
a decreased uptake of 89Zr-bevacizumab in breast and 
ovarian cancer xenografts (114,115). Downregulation 
of VEGF-A can also be the result of mTOR inhibition 
by mTOR inhibitors such as everolimus and could be 
visualized using 89Zr-bevacizumab in mice and 
humans (116, 117). Also, treatment with 
VEGFR1-3-targeting TKI, sunitinib, a TKI targeting 
VEGFR1-3 led to changes in VEGF-A tumor levels 
that could be effectively assessed by bevacizumab 
F(ab')2-fragment 89Zr-ranibizumab in ovarian and 
colon cancer xenografts (118).  
Besides measuring ligands, analysis of RTK 
expression has been used as an effect sensor for 
successful target engagement. For instance, PI3K 
inhibitor GDC-0941 and AKT inhibitor GDC-0068 led 
to upregulation of EGFR in HCC70 human breast 
cancer xenograft which could be visualized with a 
64Cu-DOTA EGFR F(ab’)2 fragment derived from 
cetuximab (119). Afatinib treatment, on the other 
hand, lowered HER2 expression in a human gastric 
cancer N87 xenograft model in mice, which was 
visualized using 89Zr-trastuzumab (120). Lapatinib, on 
the other hand, interfered with receptor dynamics by 
upregulating and stabilizing HER2 at the plasma 
membrane, ultimately leading to lower 
89Zr-trastuzumab-F(ab’)2 tracer uptake in a breast 
cancer model (121). HSP90 inhibition also 
downregulated RTKs such as IGF1R and HER2, 
which was effectively discriminated by 89Zr-mAb391 
and 89Zr-trastuzumab by PET, respectively, as well as 
by AlexaFluor680-ZHer2:342 affibodies for HER2 
with near-infrared fluorescence in breast cancer 
xenografts (Figure 2B) (115,121–124). This latter 
approach was clinically validated using HER2 as an 
effect sensor for treatment with HSP90 inhibitor 
NVP-AUY922 in HER2-positive breast cancer patients 
using 89Zr-trastuzumab PET and correlated with a 
response by computed tomography (CT) (Figure 2C) 
(125). Also, inhibition of AKT by GDC-0068 led to an 
upregulation of HER3 in patient-derived triple 
negative breast cancer xenografts, which in turn 
increased dual EGFR/HER3 antibody 
89Zr-MEHD7945A tumor uptake (126). Selective 
imaging of HER3 upregulation after GDC-0068 
treatment in MDA-MB-468 human breast cancer 
xenografts was demonstrated using 
64Cu-DOTA-HER3 F(ab’)2 (Figure 2F,G) (119). 
These are examples of HER family therapy 
effects that can be visualized and might be applied to 
adjust therapy in a timely fashion. However, only a 
few effects sensors are currently available to image 
treatment effects. This is partly because the effect 
sensor has to be excreted or expressed extracellularly 
to have accessibility to the target. This is due to the 
difficulty of high molecular weight imaging probes 
like antibodies, to cross the plasma membrane, and if 
required, the nuclear membrane.  
Imaging Intracellular processes in vivo 
Visualization of intracellular targets has been 
largely restricted to small molecule-based imaging 
tracers. In general, intracellular processes for which 
imaging is currently feasible are generic processes 
such as tumor glucose metabolism by 18F-FDG and 
cellular proliferation using 18F-FLT and 11C-thymidine 
incorporation. One strategy to overcome the hurdle 
posed by the inability of antibodies to cross 
membranes, is modifying them with the 
HIV1-derived cell-penetrating transactivator of 





transcription (TAT) peptide, to ensure nuclear 
deposition (Figure 2H) (127). Using this technique, 
111In-anti-p27kip1-TAT antibody SPECT imaging was 
able to visualize upregulation of the nuclear localized 
cyclin-dependent kinase inhibitor p27kip1 after 
trastuzumab treatment of mice bearing human breast 
cancer xenografts (128). More recently, this approach 
has also been applied for detection of DNA damage 
using a phospho-specific H2AX antibody in human 
breast cancer xenografts and during tumorigenesis in 
a transgenic BALB-neuT murine breast cancer model, 
111In- and 89Zr-labeled TAT-modified phospho-H2AX 
antibody detected DNA breaks induced by chemo 
and radiotherapy (Figure 2H,I) (129–131).  
Many targeted therapies aim to inactivate 
intracellular proteins, which currently are not 
accessible for high molecular weight imaging probes. 
Approaches similar to imaging with the 
TAT-modified phospho-H2AX antibody could be 
envisioned, where changes in the activity of 
intracellular signaling pathways, including altered 
activation status of AKT or MAPK, could be 
visualized. Imaging these targets might reveal 
whether the intended therapeutic inactivation of a 
specific intracellular target is achieved and sustained 
or whether signaling is reactivated or rewired. If the 
plasma membrane no longer posed a barrier in such 
strategies, the number of possible targets for high 
molecular weight probes would greatly increase. In 
such a scenario, imaging studies of prognostic or 
predictive markers could focus on the most relevant 
targets, and would no longer be restricted to proxies 
at the plasma membrane. 
Radiomics 
The emerging field of radiomics combines 
imaging data with ’omics’ methodology. In radiomic 
analyses, quantitative features are mined from large 
data sets of (mainly routine) medical tomographic 
imaging data such as PET, CT and MRI scans using 
bioinformatics. Examples of features comprise, 
amongst others, descriptors for shape, size, volume 
and texture in space and over time, which in turn 
might reflect underlying pathophysiology. These 
features are combined with clinical outcome data and 
other patient characteristics to develop predictive 
models for genetic and molecular characteristics, 
prognosis, as well as treatment response (132, 133).  
Tentative retrospective radiomics studies for 
prediction of HER tumor status have yielded 
encouraging results. A set of 11 radiomic features 
extracted from CT images of patients with lung 
adenocarcinoma was predictive for EGFR mutation 
status, with an area under the curve (AUC) of the 
receiver operating characteristic curve (ROC) of 0.667 
for radiomic data alone, and 0.709 when combined 
with clinical parameters (134). In another study, a 
decision tree based upon several CT textural features 
could differentiate KRAS mutants from EGFR-wt 
NSCLC patients with sensitivity, specificity, and 
accuracy of 96.3%, 81.0% and 89.6%, respectively 
(135). Radiomic features extracted from 18F-FDG PET 
in NSCLC patients could discriminate mutant EGFR 
from EGFR-wt as well as mutant EGFR from KRAS 
mutants but could make no distinction between KRAS 
mutant and EGFR-wt (136). To our knowledge, no 
radiomics studies with HER-targeted molecular 
imaging probes have been reported. However, future 
radiomic analysis of large databases of PET data from 
HER-targeted tracers, combined with clinical data, 
might help identify features for prediction of 
underlying patient phenotype and outcome.  
Platform integration to guide selection of 
novel tracers 
Both the arsenal of available tracers as well as the 
technology for molecular imaging are advancing 
rapidly. However, molecular imaging can benefit 
from other disciplines for the identification of novel 
discriminating factors. In this regard, large data sets of 
biological information can increasingly be utilized for 
the identification of the most interesting and 
informative targets for imaging. Clinical and 
pre-clinical studies progressively include ‘omics’ 
methodologies encompassing genomic, 
transcriptomic, and proteomic analyses. Combined 
with clinical outcome metrics these data yield an 
‘integrative omics’ approach. This offers great 
opportunities for extensive data mining to discover 
biomarkers which associate with tumor 
characteristics, treatment responses, and survival 
outcomes. These biomarker panels are not only useful 
to define new molecular-based tumor markers for 
molecular testing, but also provide a great resource to 
identify relevant molecular imaging targets, 
indicative of treatment effectiveness or resistance 
(137–139).  
Clinical classification using integrative omics 
Integrative omics can be applied to uncover key 
pathways that are altered in cancer by utilizing 
information from the ‘cancer genome’ with an 
associated ‘cancer proteome’ (140). Often-used 
platforms include combinations of genomics (i.e. DNA 
sequencing for mutations, copy number aberrations 
(CNAs), and methylation of genes), transcriptomics 
(microarray RNA-based or RNAseq-based expression 
analysis), and proteomic analysis (proteins abundance 
and post-translational modifications (PTMs) using 
mass spectrometry (MS) or multiplexed reverse-phase 





protein arrays (RPPA)) (Figure 3) (141). Because 
integrative omics approaches use unbiased selection 
methods, they are of potential interest for 
classification of patient groups and identification of 
biomarkers. Large-scale initiatives have attempted to 
diversify on histological cancer subtypes by 
identifying common features within the high 
information density of multiple platforms. For 
example, in-depth genomic analysis of 2,000 breast 
cancers identified 10 genetic classifications of breast 
cancer with distinct survival outcomes, although their 
clinical relevancy will need to be validated (142). 
Reassuringly, in a study of over 6,000 breast cancer 
patients, expression profiling using a panel of 70 
genes (MammaPrint) showed that adjuvant 
chemotherapy could be safely withheld in the group 
of patients with genetically low-risk hormonal breast 
cancers (143). Further in-depth analysis of gene 
expression showed how immune cell-specific gene 
patterns could be used to define the fraction of 
infiltrating immune cells within 7,270 breast cancer 
profiles. The data also identified associations between 
different tumor compositions and therapy response as 
well as the outcome for known breast cancer subtypes 
(144). Besides diversifying on single cancer types, 
integrative omics analysis can identify molecular 
patterns across cancer types. The Cancer Genome 
Atlas (TCGA) consortium, for instance, has compiled 
transcription and genomic profiling of more than 500 
tumor samples each for 11 cancer types (145). 
Meta-analysis on all combined TCGA-data sets 
uncovered new insights into shared features and 
common oncogenic drivers across tumor types and 
was used to classify tumors as being either largely 
driven by mutations or chromosomal aberrations 
(146). The potential of integrative omics to yield new 
imaging targets was indicated by an explorative 
study. Combined analyses of microarray database 
Oncomine and Gene Ontology identified not only 
known imaging targets (e.g. HER2 in breast cancer) 
but also potential imaging targets to differentiate 
between normal and cancer tissues in six different 
cancer types including MUC1 in ovarian cancer (138). 
The studies mentioned above confirmed previously 
established profiles, and more importantly, 
uncovered sub-classifications with distinct biological 
features, disease characteristics, and prognosis.  
The studies above mainly used genomic and 
transcriptomic analyses, whereas technological 
advances have significantly improved the sensitivity 
and resolution of high-throughput proteomics (147). 
Genomic and proteomic integration was recently 
applied in a large-scale analysis of TCGA colorectal 
cancer data (148). Five unique protein signatures were 
identified, which confirmed established genomic 
signatures and revealed clinically relevant cancer 
sub-populations (148). A similar approach was 
employed for the breast cancer TCGA cohort that also 
included phospho-proteomic analysis linking genetic 
alterations to changes in phosphorylated kinases 
(149). To a certain degree, protein expression is 
expected to resemble gene transcription levels, 
especially in the case of CNAs, resulting in gene 
amplifications or deletions (150). However, the 
proteogenomic analysis of TCGA data showed very 
often protein levels did not correlate well with mRNA 
levels or CNAs, underscoring the need for proteomic 
data to validate and further improve genetics-based 
classifications. This notion is particularly important 
for genomics-based selection of biomarkers intended 
for use in tissue samples or imaging. Taken together, 
omics studies have shown that (epi)genetic alterations 
give rise to a wide range of new molecular-based 
cancer classifications and large-scale genomic and 
proteomic analyses can support their identification. 
Many biomarkers are used for patient 
stratification before treatment, however, they are not 
necessarily suitable for patient follow-up during and 
after treatment. In contrast to molecular imaging that 
allows for multiple, non-invasive whole body scans 
over time, genomic biomarkers are limited by the 
number of invasive re-biopsies for follow-up 
sampling and not necessarily informative for all 
lesions due to intra-tumor heterogeneity. This can 
potentially be improved by including molecular 
imaging in treatment decisions. For example, patients 
with 89Zr-trastuzumab PET HER2-positive pattern, 
showed more clinical benefit on T-DM1 therapy when 
compared to patients with a HER2 PET-negative 
pattern (107). It is also of note, that detection of 
circulating tumor DNA (ctDNA) in blood might 
partly alleviate the difficulty of repeated invasive 
biopsies and allow for patient follow-up during 
treatment by retrospective analysis of serially 
obtained samples. For instance, a de novo EGFR 
mutation in exon 21 could be identified in circulating 
tumor DNA of a patient with recurrent ovarian cancer 
(151). Similarly, the emergence of EGFR-T790M 
mutation was detected prior to progressive disease by 
serial measurement of ctDNA in plasma of NSCLC 
patients and was associated with worse overall 










Figure 3. Omics-based strategies to facilitate discovery of novel molecular imaging targets Tissue or serum samples collected from patients, or from 
other in vivo and in vitro sources, can be analyzed by genomic, transcriptomic, and proteomic discovery platforms. The resulting profiles can then be combined by 
integrative omics approaches to develop molecular-based tumor classifications and discover potential informative biomarkers. From this integrative approach new 
protein targets or mutations could be discovered that distinguish tumor from benign tissue. Similarly, analyzing pre- and post-treatment profiles could potentially lead 
to discovery of effect sensors that signify response to treatment or emergence of resistance pathways.  
 
 
An alternative strategy to discover therapy 
response biomarkers would involve pre- and 
post-treatment analysis of the proteomic make-up of 
tumors from responders versus non-responders. Such 
an approach would define proteins that dynamically 
change depending upon the efficacy of treatment and 
as such might be used as effect sensor biomarkers. 
Pre-clinical imaging studies have shown the 
feasibility of monitoring drug-induced changes in 
protein expression with radionuclide imaging, such as 
the successful imaging of increased expression of 
EGFR and HER3 following treatment with PI3K/AKT 
TKIs using 64Cu-antibody F(ab’)2 fragments (119). 
Using this approach, potential effect sensors 





identified in omics studies could be validated with 
molecular imaging. However, large-scale proteome 
analysis of tumor samples about treatment is not 
widely performed, mainly due to the difficulty in 
obtaining post-treatment samples. Such analyses are 
certainly warranted to identify reliable markers for 
treatment response.  
Although molecular profiling studies have 
provided valuable insights in cancer subtypes, the 
question remains whether the profiles can be reliably 
measured with standard clinical techniques and if 
they truly improve the survival outcomes. Recent 
clinical trials have shown the feasibility of treatment 
based on selected biomarkers panels, whole genome, 
or proteome analysis. For example, the BATTLE trial 
assessed the feasibility of a selected set of genomic 
and proteomic biomarkers for erlotinib treatment, 
including EGFR mutations or CNA analysis, to guide 
treatment decision for NSCLC patients (153). At a 
larger scale, the WINTHER trial aims at full genomic 
analysis to stratify patients with so-called ‘actionable 
alterations’, mutations that can be targeted with 
approved or experimental treatments (154). Another 
example is the CPCT initiative in which next 
generation sequencing of tumor samples was 
performed to guide drug choice for patients with 
metastatic disease (155). It is conceivable that 
omics-based screening will identify more patients 
with actionable alterations, leading to incremental 
knowledge and increasingly predictive biomarker 
profiles. To this end, molecular imaging could play a 
role in biomarker-driven studies that focus on 
alterations that lead to changes in expressed proteins. 
To clinically test treatments based on molecular 
biomarkers, trial designs are adapted to enroll 
patients with rare mutations from multiple cancer 
types in so-called basket clinical trials. Using such a 
design, patients from 7 different cancer types 
harboring a BRAF-V600E mutation could be treated 
with the BRAF inhibitor vemurafenib (156). The 
recently launched TAPUR study (NCT02693535) 
encompasses 15 basket trials for patients with rare 
mutations. Amongst these are trials for patients with 
EGFR-mutated tumors to be treated with erlotinib, 
EGFR-wt tumors without any downstream RAS or 
RAF mutations with cetuximab, and treatment with 
trastuzumab and pertuzumab for patients with 
tumors harboring HER2 amplifications. These 
developments will give an indication of the added 
value of omics for trial designs and treatment 
guidance and offer a unique opportunity for 
molecular imaging to be incorporated in future 
profiling studies. 
Platform integration to identify novel 
biomarkers  
Biomarkers are increasingly a part of clinical 
testing for classification of cancer and differentiation 
into relevant subgroups. Activating EGFR mutations 
are targeted for effective treatment with TKIs erlotinib 
or gefitinib in NSCLC while ALK mutations or ROS1 
translocations define a subgroup responding to 
crizotinib (157). Other prototypical examples of 
genomic biomarker-based guidance for treatment 
choice are BCR-ABL translocations in chronic myeloid 
leukemia treated with imatinib, BRCA1/2 mutations in 
ovarian cancer treated with PARP inhibitors, and 
BRAF-V600E mutations in melanoma treated with 
BRAF inhibitors (158–160). Besides these genomic 
biomarkers, many tumor-expressed protein 
biomarkers have been reported, including HER2, 
estrogen receptor (ER), and progesterone receptor 
(PR) in breast cancer, and c-KIT in gastro-intestinal 
stromal tumors (161). Interestingly, these protein 
targets (except c-KIT) can be successfully monitored 
in the clinic using a diverse panel of molecular 
imaging techniques for HER2, ER, and PR (94, 162, 
163). Despite the plethora of biomarkers reported in 
the literature, only a relatively small number has been 
approved for clinical use (161). However, a renewed 
focus in precision medicine to develop targeted drugs 
together with matched biomarkers should improve 
the utility and numbers of biomarkers in the clinic 
(157). We anticipate that by providing insight into 
whole body and temporal expression of biomarkers, 
molecular imaging approaches can be one of the 
platforms to validate and apply new and existing 
tumor markers. 
Genomic changes do not translate to phenotypic 
changes per se due to, for instance, regulation of RNA 
translation or protein function affected by 
post-translational modifications (PTMs). PTMs, such 
as phosphorylation and ubiquitination, can greatly 
affect the activity, stability, and function of proteins 
and can be highly dynamic modifications. 
Proteogenomic analyses by the Clinical Proteome 
Tumor Analysis Consortium (CPTAC) on CRC and 
breast cancer TCGA tumor specimens showed that 
translational factors could be quantitatively analyzed 
by proteomics and integrated with genomics to 
validate and improve molecular profiling (148,149). 
Integration of multiple platforms allows for more 
depth of analysis and stringent selection, potentially 
leading to more successful biomarkers (164). The 
addition of proteomics to existing genomic platforms 
can determine whether genomic markers are 
functionally expressed, allows for correlation of 
metabolic and enzymatic processes with genomic 
profiles, and can be used to follow-up on serum 





biomarkers and effect sensors in time. Ultimately, this 
could lead to robust molecular imaging candidates to 
visualize drug resistance or tumor responses 
(Figure 3).  
To find new molecular imaging targets, 
proteomics can be used for validation of selected 
genomic markers or identification of new markers 
based upon the integration of proteomic and genomic 
data. For validation or measurement of a selected 
number of biomarkers after the initial discovery, 
targeted MS techniques such as multiple reaction 
monitoring-MS (MRM-MS) or reverse phase protein 
array (RPPA) are most suitable, whereas new 
biomarkers are better identified with quantitative 
proteomics. Thus far, MRM-MS has been mostly 
employed for serum biomarkers such as 
prostate-specific antigen or changes in metabolism 
(165). Serum biomarkers are extensively explored 
using proteomics and employed as diagnostic tools. 
However, serum biomarkers mostly reflect tumor 
load and do not provide information on inter- and 
intra-tumor heterogeneity making them less suitable 
as molecular imaging targets. Nevertheless, serum 
analysis can be integrated with genomics to study 
treatment responses. For instance, by analyzing 
temporal changes in gene expression and serum 
metabolites in an EGFR-L828R-T790M-driven mouse 
tumor model, it was possible to identify changes in 
metabolic pathways, such as the glutathione pathway 
essential for tumor response to EGFR TKI afatinib 
alone or in combination with the mTOR inhibitor 
rapamycin (166). As glutamine is a precursor of the 
glutathione pathway, molecular imaging with 
18F-glutamine PET in NSCLC and breast cancer 
patients might facilitate monitoring drug-induced 
changes in this pathway (167). Thus, similar 
approaches can be used to measure changes in 
metabolic or enzymatic processes identified by 
genomics and confirmed by proteomic 
measurements. In addition to imaging of the prostate 
specific membrane antigen (PSMA) to visualize 
prostate cancer, the enzymatic activity of PSMA could 
be visualized with urea-based tracers, which are 
metabolized by PSMA (152, 153). Such studies point 
to cellular processes underlying biomarkers that 
might be used for molecular imaging.  
RPPA is a promising technique for analysis of 
cellular biomarker panels, as it allows multiplexed 
assessment of markers limited only by the availability 
of specific antibodies. The combination of 
transcriptomic, genomic, and drug sensitivity data by 
RPPA analysis of 71 proteins in 84 NSCLC cell lines 
showed that sensitivity to EGFR inhibition correlated 
better with activated EGFR levels than EGFR 
abundance (160). These data are in concordance with 
the correlation between activated EGFR and EGFR 
TKI sensitivity found in clinical studies. As another 
example, a pattern of high AXL expression and c-MET 
activation was identified using RPPA in breast cancer 
tissues supposedly driving proliferation (170). Gene 
expression analysis studies have further led to the 
identification of AXL as a driver of resistance to EGFR 
TKIs in HNSCC and NSCLC models (171, 172). 
Considering that AXL imaging has already been 
performed with 64Cu-labeled (173) and NIRF-dye 
Cy5.5-conjugated AXL antibodies (174) in 
AXL-positive A549 human NSCLC xenografts in 
mice, this proliferation pathway and resistance 
mechanism to EGFR TKIs could potentially be 
monitored by non-invasive imaging. RPPA has been 
employed on a large scale targeting nearly 200 
proteins and phosphorylated variants on 4,379 tumor 
samples, largely from 11 TCGA cancer cohorts and 3 
independent cohorts (175). Although these data, so far 
only used to uncover pan-cancer proteomic relations 
in the TCGA cohorts, still provide a unique 
opportunity to integrate genomic TCGA analyses 
with proteomic data across multiple tumor types 
(176). 
Identification of novel prognostic biomarkers or 
protein-based early effect sensors should not depend 
on fixed, preselected, antibodies used in RPPA and is 
better studied with a quantitative MS-based 
proteome-wide analysis. This can be performed using 
either isotope or chemical labeling or by label-free 
quantitation. Proteogenomic analysis of the TCGA 
CRC cohort was performed with label-free analysis 
using spectral counting and expression levels of 
protein were quantified in relation to all measured 
samples (148). To accurately quantify protein 
expression changes or PTMs, knowledge of control or 
standardized expression levels is essential. To this 
end, protein-labeling techniques can be employed 
together with MS, which utilizes incorporation of 
stable isotopes in cell lines. For example, SILAC-MS 
quantifies ratios between proteins derived from stable 
isotope-labeled cell lines and their unlabeled 
counterparts from control cell cultures. This technique 
can thus be used to measure protein dynamics when a 
certain treatment is applied to one of the cell cultures 
(177). Alternatively, isotope labeling can be 
performed post-treatment on cells or patient tissues 
using standardized SILAC-labeled reference samples 
or chemical labeling using isobaric tags for the relative 
and absolute quantitation (iTRAQ) method (178). 
Using SILAC-based proteomics, increased levels of 
EGFR, Clusterin-CLU, and HADHB were found as 
potential biomarkers in trastuzumab-resistant breast 
cancer cell lines compared to their parental controls 
(179). An early proteomic response to EGFR inhibition 





by gefitinib in human NSCLC cell line A431 was also 
investigated using SILAC-MS identifying a panel of 
15 membrane proteins upregulated after gefitinib 
treatment (180). Although not clinically validated, 
these proteins identified in both studies were 
suggested as early markers of resistance to 
trastuzumab. Quantitative proteomics is, therefore, a 
promising discovery platform for new molecular 
imaging effect sensors by analyzing drug-induced 
changes in proteomes of cancer cells.  
A largely untouched area of biomarkers is PTMs 
of proteins, that can be identified using MS. SILAC- 
and iTRAQ-based MS strategies, which are highly 
effective in quantifying changes in multiple PTMs 
simultaneously, such as changes in phosphorylation, 
glycosylation, or ubiquitination (181). PTMs are 
particularly interesting molecular markers as they 
portray the underlying, highly dynamic, biologic 
processes in cancer. For example, the extensive 
phospho-proteome analysis was performed to map 
EGFR signaling in relation to the sensitivity to HER 
family inhibitors. This approach confirmed alterations 
in established downstream signaling after EGFR TKI 
treatment, while feedback pathways involving HER2 
and HER3, as well as changes in autophagy pathways 
were identified (166, 167). Furthermore, SILAC 
phospho-proteomic analysis detected high levels of 
phosphorylated EGFR in EGFR-wt pancreatic cancer 
cell lines sensitive to erlotinib, suggesting 
phosphorylated EGFR as a predictive marker for 
erlotinib treatment when EGFR mutations are absent 
(184). Using iTRAQ labeling of 105 TCGA breast 
cancer samples with corresponding genomic and 
clinical data, new correlations between genetic 
alterations (e.g. CNAs) and protein translation were 
found. For instance, loss of chromosome arm 5q 
containing SKP1 and CETN3 in basal breast cancers 
was shown as the potential cause of increased 
expression of EGFR and Src (149). Furthermore, CNAs 
could also be linked to changes in phosphorylation, as 
HER2 amplification induced over-expression and 
activation of not only HER2 but also of the 
surrounding genes CDK12, MED1, and GRB7 (149). 
Assuming the availability of specific probes for 
detection of PTMs, molecular imaging, for example 
using TAT-modified antibody strategies, would allow 
for direct analysis of pathway activation status, and 
may be more informative than analysis of the plain 
abundance of pathway components.  
Developments in genomic and proteomic 
platforms will continue to improve biomarker 
discovery that will lead to implementation in clinical 
studies. With the existing and expanding data from 
these studies, molecular imaging targets can be 
identified that can potentially guide treatment 
decisions.  
Discussion 
Development of targeted therapies and their 
implementation in clinical practice can be aided by 
molecular testing of tumor biopsies or blood-borne 
markers. Complementary to these diagnostic tools, we 
described how molecular imaging techniques could 
provide valuable information on whole body 
distribution of drug targets to aid the assessment of 
drug efficacy during treatment. Measuring target 
presence and dynamics across multiple tumor lesions 
could be highly relevant to assess drug uptake, 
especially regarding marker-dependent agents using 
toxic payloads such as ADCs. Besides 
radionuclide-based imaging strategies, advances in 
optical imaging might enable simultaneous 
visualization of multiple markers at organ-level 
resolution, removing the radiation burden and 
lowering production costs. To unveil many relevant 
intracellular processes, technical advances should be 
aimed at bringing high affinity, large molecular 
weight probes, such as antibodies and analogs past 
cellular membranes, allowing high-contrast 
visualization of intracellular processes in tumor cells. 
Whether molecular imaging of oncogenic growth 
factor receptor imaging is sufficient to assess 
treatment efficacy and resistance of HER 
family-driven cancers is currently being investigated 
in clinical trials.  
Many imaging agents are directed to commonly 
used tumor markers or drug targets to acquire a better 
understanding of target distribution and behavior. 
However, this array of markers can be greatly 
expanded by making use of integrative omics 
approaches that link patient and tumor characteristics 
to genomic and proteomic analysis. From these 
efforts, molecular markers have been discovered that 
distinguish specific subsets of cancers that could be 
assessed by molecular imaging. Similarly, radiomics 
approaches combine patient and tumor 
characteristics, including mutation status, for 
computational analysis of molecular imaging data to 
discover prognostic or predictive features for 
treatment response and outcome. Key oncogenic 
tumor targets or distinguishing tumor markers 
identified by omics approaches are not often the ideal 
extracellular imaging targets. However, new 
technologies in intracellular localization of imaging 
tracers might enable monitoring the activation status 
of these relevant biological components. Lastly, there 
is an unmet opportunity for pre- and post-treatment 
imaging of effect sensors that can be discovered by 
omics analysis of serially obtained tumor samples. 





In summary, an extensive arsenal of molecular 
probes is already available to image HER family 
members and related proteins. Coupled to 
omics-based discovery platforms, this can open up an 
arsenal of other novel tracers for monitoring 
treatment efficacy and drug resistance.  
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